These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 18459587)
1. MIB-1 counting methods in meningiomas and agreement among pathologists. Rezanko T; Akkalp AK; Tunakan M; Sari AA Anal Quant Cytol Histol; 2008 Feb; 30(1):47-52. PubMed ID: 18459587 [TBL] [Abstract][Full Text] [Related]
2. Diagnostic validity of the Ki-67 labeling index using the MIB-1 monoclonal antibody in the grading of meningiomas. Devaprasath A; Chacko G Neurol India; 2003 Sep; 51(3):336-40. PubMed ID: 14652433 [TBL] [Abstract][Full Text] [Related]
3. The significance of Ki-67/MIB-1 labeling index in human meningiomas: a literature study. Abry E; Thomassen IØ; Salvesen ØO; Torp SH Pathol Res Pract; 2010 Dec; 206(12):810-5. PubMed ID: 20951502 [TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of Ki-67/MIB-1 proliferation index in meningiomas. Torp SH; Lindboe CF; Grønberg BH; Lydersen S; Sundstrøm S Clin Neuropathol; 2005; 24(4):170-4. PubMed ID: 16033133 [TBL] [Abstract][Full Text] [Related]
5. Significance of MIB-1 staining indices in meningiomas: comparison of two counting methods. Nakasu S; Li DH; Okabe H; Nakajima M; Matsuda M Am J Surg Pathol; 2001 Apr; 25(4):472-8. PubMed ID: 11257621 [TBL] [Abstract][Full Text] [Related]
6. Correlation between histological grade and MIB-1 and p53 immunoreactivity in meningiomas. Ozen O; Demirhan B; Altinörs N Clin Neuropathol; 2005; 24(5):219-24. PubMed ID: 16167545 [TBL] [Abstract][Full Text] [Related]
7. The Ki-67 proliferation antigen in meningiomas. Experience in 600 cases. Roser F; Samii M; Ostertag H; Bellinzona M Acta Neurochir (Wien); 2004 Jan; 146(1):37-44; discussion 44. PubMed ID: 14740263 [TBL] [Abstract][Full Text] [Related]
8. Correlation between histological grade, MIB-1, p53, and recurrence in 69 completely resected primary intracranial meningiomas with a 6 year mean follow-up. Lanzafame S; Torrisi A; Barbagallo G; Emmanuele C; Alberio N; Albanese V Pathol Res Pract; 2000; 196(7):483-8. PubMed ID: 10926326 [TBL] [Abstract][Full Text] [Related]
9. Intracranial meningeal tumours in childhood: a clinicopathologic study including MIB-1 immunohistochemistry. Demirtaş E; Erşahin Y; Yilmaz F; Mutluer S; Veral A Pathol Res Pract; 2000; 196(3):151-8. PubMed ID: 10729919 [TBL] [Abstract][Full Text] [Related]
10. Histopathologic features and MIB-1 labeling indices in recurrent and nonrecurrent meningiomas. Abramovich CM; Prayson RA Arch Pathol Lab Med; 1999 Sep; 123(9):793-800. PubMed ID: 10458826 [TBL] [Abstract][Full Text] [Related]
11. MIB-1 labeling indices in benign, aggressive, and malignant meningiomas: a study of 90 tumors. Abramovich CM; Prayson RA Hum Pathol; 1998 Dec; 29(12):1420-7. PubMed ID: 9865827 [TBL] [Abstract][Full Text] [Related]
12. Correlation Between Digital and Manual Determinations of Ki-67/MIB-1 Proliferative Indices in Human Meningiomas. Pham DT; Skaland I; Winther TL; Salvesen Ø; Torp SH Int J Surg Pathol; 2020 May; 28(3):273-279. PubMed ID: 31771372 [No Abstract] [Full Text] [Related]
13. Sensitivity and usefulness of anti-phosphohistone-H3 antibody immunostaining for counting mitotic figures in meningioma cases. Fukushima S; Terasaki M; Sakata K; Miyagi N; Kato S; Sugita Y; Shigemori M Brain Tumor Pathol; 2009; 26(2):51-7. PubMed ID: 19856215 [TBL] [Abstract][Full Text] [Related]
14. Clinical and histopathological analysis of proliferative potentials of recurrent and non-recurrent meningiomas. Matsuno A; Fujimaki T; Sasaki T; Nagashima T; Ide T; Asai A; Matsuura R; Utsunomiya H; Kirino T Acta Neuropathol; 1996; 91(5):504-10. PubMed ID: 8740231 [TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical study of Ki-67 (MIB-1), p53 protein, p21WAF1, and p27KIP1 expression in benign, atypical, and anaplastic meningiomas. Amatya VJ; Takeshima Y; Sugiyama K; Kurisu K; Nishisaka T; Fukuhara T; Inai K Hum Pathol; 2001 Sep; 32(9):970-5. PubMed ID: 11567227 [TBL] [Abstract][Full Text] [Related]
16. MIB-1 (Ki-67) index and transforming growth factor-alpha (TGF alpha) immunoreactivity are significant prognostic predictors for meningiomas. Hsu DW; Efird JT; Hedley-Whyte ET Neuropathol Appl Neurobiol; 1998 Dec; 24(6):441-52. PubMed ID: 9888154 [TBL] [Abstract][Full Text] [Related]
17. Interobserver reproducibility of MIB-1 labeling index in astrocytic tumors using different counting methods. Hsu CY; Ho DM; Yang CF; Chiang H Mod Pathol; 2003 Sep; 16(9):951-7. PubMed ID: 13679460 [TBL] [Abstract][Full Text] [Related]
18. [Analysis of the proliferative potential of meningiomas with MIB-1 monoclonal antibodies]. Miyagami M; Shibuya T; Miyagi A; Tsubokawa T No To Shinkei; 1996 Jan; 48(1):39-43. PubMed ID: 8679317 [TBL] [Abstract][Full Text] [Related]
19. Meningiomas: Objective assessment of proliferative indices by immunohistochemistry and automated counting method. Chavali P; Uppin MS; Uppin SG; Challa S Neurol India; 2017; 65(6):1345-1349. PubMed ID: 29133712 [TBL] [Abstract][Full Text] [Related]
20. MIB-1 immunolabeling: a valuable marker in prediction of benign recurring meningiomas. Vankalakunti M; Vasishta RK; Das Radotra B; Khosla VK Neuropathology; 2007 Oct; 27(5):407-12. PubMed ID: 18018472 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]